Lantern Pharma — Third Quarter 2026 Earnings Summary
Financial Performance:
- Cash, cash equivalents, and marketable securities were approximately $7.6 million as of September 30, 2026, down from approximately $10.1 million as of December 31, 2025.
- Research and development expenses decreased approximately 36% year-over-year to approximately $1.6 million for Q3 2026, compared to $2.4 million in Q3 2025.
- General and administrative expenses increased approximately 99% year-over-year to approximately $3.8 million for Q3 2026, compared to $1.9 million in Q3 2025; excluding a $2.0 million settlement accrual, G&A was approximately $1.8 million, a 5% decrease year-over-year.
- Loss from operations was approximately $5.4 million for Q3 2026, compared to $4.3 million in Q3 2025; excluding the $2.0 million settlement accrual, loss from operations was approximately $3.4 million, a 22% decrease year-over-year.
- Net income was approximately $0.7 million ($0.05 per basic share) for Q3 2026, compared to a net loss of $4.2 million ($0.39 per share) in Q3 2025, driven by a non-cash warrant gain of approximately $6.0 million.
- The company recorded a non-cash gain of approximately $6.0 million due to a decrease in the fair value of warrant liabilities associated with the May 2026 offering, which were remeasured as liabilities.
- Warrant liability was approximately $1.5 million as of September 30, 2026.
- The company stated that its cash resources as of the date of the Q3 2026 10-Q are not sufficient to fund operations for the next 12 months, noting substantial doubt about its ability to continue as a going concern without additional funding.
Guidance and Future Outlook:
- The company intends to pursue periodic capital raises, including potential sales under its ATM facility, as well as collaborations, grant funding, and other opportunities to extend its operating runway.
- The Board intends to promptly commence a search for a permanent Chief Executive Officer following the appointment of an interim CEO.
- The company is exploring regional licensing, partnering, and co-development opportunities for LP-300 in East Asia.
- Open Medicine AI plans to expand beyond rare cancers and oncology into additional high-need disease areas through collaboration with academic and commercial partners.
- The company anticipates IRB approval at two additional Taiwan sites for the HARMONIC™ trial during the fourth quarter of 2026.
Business Segments and Product Lines:
- LP-300 (HARMONIC™ Trial): Part 2 of the Phase 2 trial opened in Taiwan and the U.S. in September 2026; the lead Taiwan site is open to accrual and screening. The trial enrolls never-smoker patients with EGFR exon 21 L858R mutation, extending dosing from six to a maximum of eight cycles.
- LP-184 (zirdafulven): The first clinical site for a Phase 1b/2 trial in triple-negative breast cancer (TNBC) was engaged in November 2026 to begin enrollment; the drug has Fast Track designation for this indication.
- LP-184 (Glioblastoma): Peer-reviewed Phase 1a data published in October 2026 supports a planned Phase 1b/2a combination trial with spironolactone (STAR-001) under an FDA-cleared IND.
- LP-184 (Bladder Cancer): An EMA-cleared, investigator-initiated Phase 1b/2 trial in biomarker-selected advanced bladder cancer is open for enrollment at Rigshospitalet in Copenhagen, Denmark.
- LP-284: A Phase 1a clinical trial is ongoing in hematologic malignancies and adult soft tissue sarcomas; the USPTO issued a Notice of Allowance for a patent covering the use of LP-284 to treat mantle cell lymphoma and double-hit lymphoma.
- STAR-001 (Pediatric CNS): A subsidiary holds a cleared IND for a planned Phase 1 pediatric CNS cancer trial of LP-184.
- Open Medicine AI: Formed in July 2026 as a wholly-owned subsidiary to commercialize the multi-agentic AI co-scientist platform (formerly withZeta.ai), granting access to Lantern's models, data, and algorithms.
Market and Competitive Landscape:
- Taiwan offers a large patient population for the HARMONIC™ trial, with over half of lung cancer patients being never-smokers and EGFR mutations found in 55% of advanced lung adenocarcinomas.
- The L858R mutation is more common in Asian patients compared to European (14%) and U.S. (24%) populations.
- Taiwan's National Health Insurance reimburses next-generation sequencing at the time of drug resistance, expected to support efficient enrollment.
- The company leverages its RADR® platform, which utilizes over 200 billion oncology-focused data points and 200+ advanced ML algorithms.
Risks and Challenges:
- Substantial doubt exists regarding the company's ability to continue as a going concern due to insufficient cash to fund operations for the next 12 months.
- The proposed $2.0 million settlement with a former consultant is not yet finalized or effective, and the accrued amount could change materially.
- Clinical data referenced in the release are preliminary, exploratory, and based on small patient cohorts, with no assurance that results will be reproduced in larger studies.
- No product candidates have received marketing approval from the FDA, EMA, or other regulatory authorities.
- There is a risk that the AI platform commercialization efforts may not generate anticipated revenue or achieve market adoption.
- The company faces risks related to leadership transition and the potential failure of clinical trials to initiate, enroll, or complete on anticipated timelines.
Management Commentary and Tone:
- Panna Sharma resigned as President and CEO and from the Board of Directors effective November 15, 2026.
- David Margrave, the Chief Financial Officer, was appointed Interim Chief Executive Officer effective November 16, 2026.
- Management highlighted the closure of a registered direct offering for approximately $4.0 million in gross proceeds on September 30, 2026.
- The company noted that R&D expense reductions were primarily due to decreases in research studies and materials costs.
Analyst Questions and Answers:
- No analyst questions and answers were included in the press release.
Other Key Points:
- The company closed a registered direct offering and concurrent private placement on September 30, 2026, for gross proceeds of approximately $4.0 million, before offering expenses of approximately $0.4 million.
- The offering included 1,469,725 shares of common stock at $1.09 per share, pre-funded warrants for up to 2,200,000 shares, and warrants for up to 3,669,725 shares at an exercise price of $1.09 per share.
- A $2.0 million accrual was recorded for a proposed settlement with a former part-time consultant regarding claims of disability discrimination and sexual harassment; payment terms include $1.0 million within 30 days and $1.0 million upon raising $10.0 million in gross cash proceeds or the two-year anniversary of the first payment.
- As of November 9, 2026, the company had 15,886,576 shares of common stock outstanding.
- The company established Starlight Therapeutics as a subsidiary to focus exclusively on clinical execution for CNS and brain cancers.
- Company
- LANTERN PHARMA INC
- Sector
- Healthcare
- Industry
- Biotechnology